Total Payments
$262,872
2024 Payments
$28,558
Companies
61
Transactions
1,231
Medicare Patients
4,836
Medicare Billing
$2.2M
Payment Breakdown by Category
Other$160,081 (60.9%)
Consulting$61,318 (23.3%)
Travel$20,339 (7.7%)
Food & Beverage$19,365 (7.4%)
Research$1,353 (0.5%)
Education$416.60 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $142,331 | 96 | 54.1% |
| Consulting Fee | $61,318 | 20 | 23.3% |
| Travel and Lodging | $20,339 | 88 | 7.7% |
| Food and Beverage | $19,365 | 1,002 | 7.4% |
| Honoraria | $17,750 | 8 | 6.8% |
| Unspecified | $1,353 | 5 | 0.5% |
| Education | $416.60 | 12 | 0.2% |
Payments by Type
General
$261,520
1,226 transactions
Research
$1,353
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $91,069 | 145 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $45,333 | 200 | $0 (2021) |
| Sarepta Therapeutics, Inc. | $20,808 | 31 | $0 (2022) |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $17,086 | 39 | $0 (2024) |
| ARGENX US, INC. | $17,081 | 18 | $0 (2024) |
| UCB, Inc. | $16,926 | 33 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $13,608 | 51 | $0 (2021) |
| Grifols USA, LLC | $10,193 | 26 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $8,807 | 8 | $0 (2024) |
| Biogen, Inc. | $7,147 | 37 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,558 | 56 | UCB, Inc. ($16,701) |
| 2023 | $30,844 | 43 | Alexion Pharmaceuticals, Inc. ($10,656) |
| 2022 | $11,677 | 16 | Alexion Pharmaceuticals, Inc. ($9,545) |
| 2021 | $9,825 | 165 | Alexion Pharmaceuticals, Inc. ($5,508) |
| 2020 | $15,575 | 157 | Alexion Pharmaceuticals, Inc. ($5,989) |
| 2019 | $43,663 | 245 | Alexion Pharmaceuticals, Inc. ($30,104) |
| 2018 | $55,788 | 273 | Alexion Pharmaceuticals, Inc. ($24,417) |
| 2017 | $66,943 | 276 | Teva Pharmaceuticals USA, Inc. ($32,647) |
All Payment Transactions
1,231 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | ARGENX US, INC. | VYVGART (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,562.50 | General |
| Category: Immunology | ||||||
| 12/03/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $16.08 | General |
| Category: Immunology | ||||||
| 11/12/2024 | UCB, Inc. | Rystiggo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,080.00 | General |
| Category: Neurology | ||||||
| 10/30/2024 | UCB, Inc. | Zilbrysq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: Neurology | ||||||
| 10/30/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | Cash or cash equivalent | $66.15 | General |
| Category: Neurology | ||||||
| 10/30/2024 | UCB, Inc. | Zilbrysq (Drug) | Travel and Lodging | Cash or cash equivalent | $20.10 | General |
| Category: Neurology | ||||||
| 10/30/2024 | UCB, Inc. | Zilbrysq (Drug) | Travel and Lodging | Cash or cash equivalent | $18.00 | General |
| Category: Neurology | ||||||
| 10/30/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | Cash or cash equivalent | $11.34 | General |
| Category: Neurology | ||||||
| 10/30/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | Cash or cash equivalent | $8.59 | General |
| Category: Neurology | ||||||
| 10/29/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: Genetic Disease | ||||||
| 10/28/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: Neurology | ||||||
| 10/21/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $3.93 | General |
| Category: NEUROSCIENCE | ||||||
| 10/12/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: PAIN | ||||||
| 10/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,547.50 | General |
| Category: IMMUNOLOGY | ||||||
| 10/04/2024 | UCB, Inc. | Zilbrysq (Drug) | Travel and Lodging | In-kind items and services | $170.02 | General |
| Category: Neurology | ||||||
| 10/04/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: Neurology | ||||||
| 10/03/2024 | UCB, Inc. | Zilbrysq (Drug) | Travel and Lodging | In-kind items and services | $696.95 | General |
| Category: Neurology | ||||||
| 10/03/2024 | UCB, Inc. | Zilbrysq (Drug) | Travel and Lodging | In-kind items and services | $245.58 | General |
| Category: Neurology | ||||||
| 09/26/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: Rare Disease | ||||||
| 09/24/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/24/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Genetic Disease | ||||||
| 09/06/2024 | UCB, Inc. | Zilbrysq (Drug) | Travel and Lodging | In-kind items and services | $60.00 | General |
| Category: Neurology | ||||||
| 08/27/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: Rare Disease | ||||||
| 08/13/2024 | UCB, Inc. | Zilbrysq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Neurology | ||||||
| 07/25/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $26.64 | General |
| Category: Genetic Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | Alexion Pharmaceuticals, Inc. | $1,353 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 1,442 | 28,305 | $2.4M | $732,957 |
| 2022 | 31 | 1,210 | 12,219 | $571,167 | $193,973 |
| 2021 | 23 | 1,048 | 29,118 | $3.5M | $672,807 |
| 2020 | 27 | 1,136 | 28,214 | $3.4M | $613,953 |
Total Patients
4,836
Total Services
97,856
Medicare Billing
$2.2M
Procedure Codes
122
All Medicare Procedures & Services
122 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 11 | 15,290 | $1.7M | $515,354 | 30.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 355 | 658 | $148,215 | $55,018 | 37.1% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 17 | 9,950 | $77,560 | $49,431 | 63.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 218 | 259 | $40,700 | $16,300 | 40.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 23 | 222 | $47,790 | $10,172 | 21.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 49 | 49 | $21,560 | $7,493 | 34.8% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 109 | 202 | $27,864 | $6,913 | 24.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 58 | 58 | $17,825 | $6,816 | 38.2% |
| 88319 | Evaluation of specimen enzymes | Office | 2023 | 31 | 180 | $16,260 | $6,248 | 38.4% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 17 | 402 | $44,220 | $6,004 | 13.6% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 44 | 44 | $35,323 | $5,960 | 16.9% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 43 | 47 | $26,268 | $4,923 | 18.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $14,175 | $4,759 | 33.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 62 | 79 | $21,689 | $4,672 | 21.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 17 | 51 | $30,600 | $4,664 | 15.2% |
| 88314 | Special stained specimen slides to examine tissue and frozen preparation of specimen including interpretation and report | Office | 2023 | 32 | 164 | $12,414 | $4,046 | 32.6% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Office | 2023 | 33 | 133 | $16,900 | $3,807 | 22.5% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2023 | 17 | 17 | $13,945 | $2,433 | 17.4% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Office | 2023 | 33 | 67 | $8,500 | $2,307 | 27.1% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2023 | 12 | 12 | $13,480 | $2,249 | 16.7% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 33 | 67 | $9,276 | $2,161 | 23.3% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 22 | 22 | $10,956 | $1,975 | 18.0% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 14 | 35 | $7,000 | $1,965 | 28.1% |
| 88348 | Electron microscopy for diagnosis | Office | 2023 | 15 | 16 | $5,580 | $1,486 | 26.6% |
| 95937 | Testing of nerve-muscle junction | Office | 2023 | 13 | 17 | $3,760 | $1,226 | 32.6% |
About Dr. Tulio Bertorini, MD
Dr. Tulio Bertorini, MD is a Neurology healthcare provider based in Memphis, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760459168.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tulio Bertorini, MD has received a total of $262,872 in payments from pharmaceutical and medical device companies, with $28,558 received in 2024. These payments were reported across 1,231 transactions from 61 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($142,331).
As a Medicare-enrolled provider, Bertorini has provided services to 4,836 Medicare beneficiaries, totaling 97,856 services with total Medicare billing of $2.2M. Data is available for 4 years (2020–2023), covering 122 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology
- Location Memphis, TN
- Active Since 03/03/2006
- Last Updated 01/13/2022
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1760459168
Products in Payments
- COPAXONE (Drug) $44,183
- SOLIRIS (Drug) $43,759
- ULTOMIRIS (Biological) $22,099
- VYVGART (Drug) $17,063
- Radicava (Drug) $15,844
- NUEDEXTA (Drug) $13,543
- EXONDYS 51 (Drug) $11,898
- Zilbrysq (Drug) $11,483
- Gamunex-C (Biological) $10,273
- HYQVIA (Biological) $8,801
- SPINRAZA (Biological) $6,806
- Exondys 51 (Drug) $5,876
- Rystiggo (Drug) $5,218
- Soliris (Drug) $4,961
- DISEASE STATE (Drug) $2,682
- Privigen (Biological) $1,523
- ULTOMIRIS (Drug) $1,353
- EXSERVAN (Drug) $1,100
- BOTOX (Biological) $846.28
- APTIOM (Drug) $527.62
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Memphis
Dr. Lucas Elijovich, Md, MD
Neurology — Payments: $467,370
Neurology $467,370
Dr. Mark Ledoux, Md, MD
Neurology — Payments: $425,881
Neurology $425,881
Dr. Lora Mcgill, M.d, M.D
Neurology — Payments: $137,944
Neurology $137,944
Rozita Khalili, Md, MD
Neurology — Payments: $90,621
Neurology $90,621
Michael Jacewicz, Md, MD
Neurology — Payments: $55,440
Neurology $55,440
Michael Levin, M.d, M.D
Neurology — Payments: $37,188
Neurology $37,188